548 related articles for article (PubMed ID: 15670193)
1. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.
Mannavola D; Persani L; Vannucchi G; Zanardelli M; Fugazzola L; Verga U; Facchetti M; Beck-Peccoz P
Clin Endocrinol (Oxf); 2005 Feb; 62(2):176-81. PubMed ID: 15670193
[TBL] [Abstract][Full Text] [Related]
2. Macro- and microadenoma of thyrotropin secreting pituitary tumors--two clinical cases.
Hubalewska-Hola A; Fröss K; Kostecka-Matyja M; Sowa-Staszczak A; Szybiński Z; Huszno B; Ptak M
Przegl Lek; 2003; 60(11):768-71. PubMed ID: 15058054
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
4. [Monosymptomatic hyperthyroidism and TSH-producing adenoma: successful therapy with octreotide].
Mayinger B; Axelos D; Pavel M; Hahn EG; Hensen J
Dtsch Med Wochenschr; 1999 Jan; 124(4):73-8. PubMed ID: 10071603
[TBL] [Abstract][Full Text] [Related]
5. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M
Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy.
Losa M; Fortunato M; Molteni L; Peretti E; Mortini P
Minerva Endocrinol; 2008 Dec; 33(4):329-40. PubMed ID: 18923369
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
Zhang CF; Liang D; Zhong LY
Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
9. Hyperthyroidism, inappropriate plasma TSH and pituitary adenoma in three patients, two receiving long-term phenothiazine therapy.
Dunne FP; Feely MP; Ferriss JB; Keohane C; Murphy D; Perry I
Q J Med; 1990 Apr; 75(276):345-54. PubMed ID: 2117296
[TBL] [Abstract][Full Text] [Related]
10. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
Iglesias P; Díez JJ
J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
[TBL] [Abstract][Full Text] [Related]
11. Hyperthyroidism caused by an ectopic thyrotropin-secreting tumor of the nasopharynx: a case report and review of the literature.
Tong A; Xia W; Qi F; Jin Z; Yang D; Zhang Z; Li F; Xing X; Lian X
Thyroid; 2013 Sep; 23(9):1172-7. PubMed ID: 23402621
[TBL] [Abstract][Full Text] [Related]
12. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
13. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995.
Beck-Peccoz P; Mariotti S; Guillausseau PJ; Medri G; Piscitelli G; Bertoli A; Barbarino A; Rondena M; Chanson P; Pinchera A
J Clin Endocrinol Metab; 1989 Jan; 68(1):208-14. PubMed ID: 2491862
[TBL] [Abstract][Full Text] [Related]
15. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.
Comi RJ; Gesundheit N; Murray L; Gorden P; Weintraub BD
N Engl J Med; 1987 Jul; 317(1):12-7. PubMed ID: 2884564
[TBL] [Abstract][Full Text] [Related]
16. Hyperthyroidism due to non-tumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995).
Williams G; Kraenzlin M; Sandler L; Burrin J; Law A; Bloom S; Joplin GF
Acta Endocrinol (Copenh); 1986 Sep; 113(1):42-6. PubMed ID: 2876571
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
18. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
Chayen SD; Gross D; Makhoul O; Glaser B
Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557
[TBL] [Abstract][Full Text] [Related]
19. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
20. [Thyroid-stimulating hormone hypophyseal adenoma. A case report].
Gannage MH; Maacaron C; Okais N; Halaby G
J Med Liban; 1997; 45(2):97-101. PubMed ID: 9289506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
